Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients

Biological Psychiatry

Volumn 53, Issue 12, 2003, Pages 1142-1145

  Dolder, Christian R ^a,b   Jeste, Dilip V ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Aging; Antipsychotic; Incidence; Psychosis; Schizophrenia; Tardive dyskinesia

Indexed keywords

BENZATROPINE; CHLORPROMAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; THIORIDAZINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HIGH RISK POPULATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TARDIVE DYSKINESIA;

EID: 0037501364     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(03)00170-7     Document Type: Article

References (23)

1. Breslow N.E. A generalized Kruskal-Wallis test for comparing K samples subject to unequal pattern of censorship. Biometrika. 57:1970;579-594.
2. Casey D.E. Tardive dyskinesia and atypical antipsychotics drugs. Schizophr Res. 35:1999;S61-S66.
3. Chouinard G., Annable L., Ross-Chouinard A., Mercier P. A 5-year prospective longitudinal study of tardive dyskinesia Factors predicting appearance of new cases . J Clin Psychopharmacol. 8:1988;21S-26S.
4. Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan G.W., et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 13:1993;25-40.
5. Cutler S.J., Ederer F. Maximum utilization of the life table method in analyzing survival. J Chronic Disord. 8:1958;669-712.
6. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state A practical method for grading the cognitive state of patients for the clinician . J Psychiatr Res. 12:1975;189-198.
7. Glick I.D., Murray S.R., Vasudevan P., Marder S.R., Hu R.J. Treatment with atypical antipsychotics New indications and new populations . J Psychiatr Res. 35:2001;187-191.
8. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 6:1967;278-296.
9. Jeste D.V., Caligiuri M.P., Paulsen J.S., Heaton R.K., Lacro J.P., Harris M.J., et al. Risk of tardive dyskinesia in older patients A prospective longitudinal study of 266 patients . Arch Gen Psychiatry. 52:1995;756-765.
10. Jeste D.V., Lacro J.P., Nguyen H.A., Petersen M.E., Rockwell E., Sewell D.D., et al. Incidence of tardive dyskinesia with risperidone versus haloperidol. J Am Geriatr Soc. 47:1999;716-719.
11. Jeste D.V., Rockwell E., Harris M.J., Lohr J.B., Lacro J. Conventional vs newer antipsychotics in elderly patients. Am J Geriatr Psychiatry. 7:1999;70-76.
12. Jeste D.V., Wyatt R.J. Treatment of tardive dyskinesia: Review of the literature. Jeste D.V., Wyatt R.J. Understanding and Treating Tardive Dyskinesia. 1982;215-288 The Guilford Press, New York.
13. Kane J.M., Jeste D.V., Barnes T.R.E., Casey D.E., Cole J.O., Davis J.M., et al. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. 1992;American Psychiatric Association, Washington, DC.
14. Kane J.M., Woerner M.G., Pollack S., Safferman A.Z., Lieberman J.A. Does clozapine cause tardive dyskinesia? J Clin Psychiatry. 54:1993;327-330.
15. Lieberman J., Kane J., Woerner M. Prevalence of tardive dyskinesia in elderly samples. Psychopharmacol Bull. 20:1984;22-26.
16. Morgenstern H., Glazer W.M. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications Results of the Yale Tardive Dyskinesia Study . Arch Gen Psychiatry. 50:1993;723-733.
17. Abnormal Involuntary Movement Scale (AIMS). Early Clin Drug Eval Unit Intercom. 4:1975;3-6.
18. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale (BPRS) Recent developments in ascertainment and scaling . Psychopharmacol Bull. 24:1988;97-99.
19. Saltz B.L., Woerner M.G., Kane J.M., Lieberman J.A., Alvir J.M., Bergmann K.J., et al. Prospective study of tardive dyskinesia incidence in the elderly. JAMA. 266:1991;2402-2406.
20. Schooler N., Kane J.M. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 39:1982;486-487.
21. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 212:1970;11-19.
22. Tandon R., Jibson M.D. Extrapyramidal side effects of antipsychotic treatment Scope of problem and impact on outcome . Ann Clin Psychiatry. 14:2002;123-129.
23. Tollefson G.D., Beasley C.M., Tamura R.N., Tran P.V., Potvin J.H. Blind, controlled, long-term study of the comparative incidence of treatment-emerged tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry. 154:1997;1248-1254.